We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Patterson Companies, Inc. (PDCO) - free report >>
Sabre Corporation (SABR) - free report >>
Jerash Holdings (US), Inc. (JRSH) - free report >>
Image: Bigstock
New Strong Sell Stocks for July 2nd
Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:
Patterson Companies, Inc. (PDCO - Free Report) distributes and sells dental and animal health products. The Zacks Consensus Estimate for its current year earnings has been revised 3.8% downward over the last 30 days.
Sabre Corporation (SABR - Free Report) provides software and technology solutions for the travel industry. The Zacks Consensus Estimate for its current year earnings has been revised 24.8% downward over the last 30 days.
Jerash Holdings (US), Inc. (JRSH - Free Report) manufactures and exports customized and readymade sport and outerwear. The Zacks Consensus Estimate for its current year earnings has been revised 7.4% downward over the last 30 days.
Upwork Inc. (UPWK - Free Report) operates an online talent marketplace. The Zacks Consensus Estimate for its current year earnings has been revised 52.9% downward over the last 60 days.
ThermoGenesis Holdings, Inc. (THMO - Free Report) develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor and other cell-based therapies. The Zacks Consensus Estimate for its current year earnings has been revised 75% downward over the last 60 days.
View the entire Zacks Rank #5 List.